1ZL Stock Overview
Develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Zai Lab Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.10 |
| 52 Week High | US$31.60 |
| 52 Week Low | US$12.40 |
| Beta | 1.11 |
| 1 Month Change | 37.12% |
| 3 Month Change | -0.55% |
| 1 Year Change | -40.85% |
| 3 Year Change | -86.39% |
| 5 Year Change | -22.65% |
| Change since IPO | -24.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1ZL | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.2% | -1.6% | -0.9% |
| 1Y | -40.8% | -26.8% | 4.5% |
Return vs Industry: 1ZL underperformed the German Biotechs industry which returned -26.8% over the past year.
Return vs Market: 1ZL underperformed the German Market which returned 4.5% over the past year.
Price Volatility
| 1ZL volatility | |
|---|---|
| 1ZL Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 1ZL's share price has been volatile over the past 3 months.
Volatility Over Time: 1ZL's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 2,175 | Samantha Du | www.zailaboratory.com |
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients.
Zai Lab Limited Fundamentals Summary
| 1ZL fundamental statistics | |
|---|---|
| Market cap | €1.83b |
| Earnings (TTM) | -€312.75m |
| Revenue (TTM) | €268.57m |
6.8x
P/S Ratio-5.9x
P/E RatioIs 1ZL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1ZL income statement (TTM) | |
|---|---|
| Revenue | US$291.07m |
| Cost of Revenue | US$380.14m |
| Gross Profit | -US$89.07m |
| Other Expenses | US$249.88m |
| Earnings | -US$338.95m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.42 |
| Gross Margin | -30.60% |
| Net Profit Margin | -116.45% |
| Debt/Equity Ratio | 6.3% |
How did 1ZL perform over the long term?
See historical performance and comparison